- Philip Morris International Inc (NYSE:PM) reported fourth-quarter FY22 sales growth of 0.6% year-on-year to $8.15 billion, beating the consensus of $7.58 billion.
- Excluding Russia and Ukraine, net revenues increased by 7.9% on an organic basis, and total shipment volume increased by 2.6%.
- Cigarette and Heated Tobacco unit shipment volume in Q4 rose by 1.2% Y/Y, with 11.3% growth in East Asia and Australia.
- Marlboro cigarette shipment volume decreased by 3.1%. Chesterfield shipment volume jumped 7.7%, and Parliament saw an 8.2% hike.
- Revenue from smoke-free products accounted for 36.0% of total net revenues, or 35.6% excluding Russia and Ukraine.
- Adjusted operating margin for the quarter compressed from 37.4% to 36.5%, with $2.9 billion in adjusted operating income.
- Adjusted EPS of $1.39 beat the consensus of $1.24.
- The company held $3.2 billion in cash and equivalents as of Dec. 31, 2022.
- Outlook: Philip Morris expects FY23 adjusted EPS of $6.25 – $6.37 and adjusted EPS, ex-currency, of $6.40 – $6.52.
- Price Action: PM shares are trading higher by 0.36% at $101.65 on the last check Thursday.
Biodexa Enters Into Exclusive License To eRapa, A Phase 3 Ready Asset For The Treatment Of Familial Adenomatous Polyposis; Worldwide Rights Come With $17M In Non-Dilutive Grant Funding For Pivotal Phase 3 Trial In FAP
Biodexa Pharmaceuticals PLC("Biodexa" or the "Company")Biodexa Enters Into Exclusive License to eRapa™, a Phase 3 Ready Asset for theTreatment of Familial Adenomatous Polyposis (FAP)Worldwide rights come with $17
